6533b822fe1ef96bd127d836

RESEARCH PRODUCT

CUL4A, ERCC5, and ERCC1 as Predictive Factors for Trabectedin Efficacy in Advanced Soft Tissue Sarcomas (STS): A Spanish Group for Sarcoma Research (GEIS) Study

José Antonio López-guerreroJosé Antonio López-guerreroMiguel TaronMiguel TaronPaloma Santos-fernandezElena Blanco-alcainaJose L. Mondaza-hernandezPaula Martinez-delgadoSerena LacerenzaRafael RamosPaloma Sanchez-bustosAntonio GutierrezAntonio Fernandez-serraIrene Carrasco-garciaDavid S. MouraNadia HindiAngela Gavilan-naranjoMaria Lopez-alvarezSamuel Hidalgo-riosJavier Martin-broto

subject

0301 basic medicineOncologyCancer Researchmedicine.medical_specialtylcsh:RC254-282Articlepredictive biomarkers03 medical and health sciences0302 clinical medicinePredictive biomarkersInternal medicineGene expressionmedicineDoxorubicinTrabectedinbusiness.industrySoft tissue sarcomasoft-tissue sarcomalcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensmedicine.disease030104 developmental biologyOncology030220 oncology & carcinogenesistrabectedinSoft-tissue sarcomaImmunohistochemistryCUL4ASarcomaERCC1CUL4AERCC1businessTrabectedinmedicine.drug

description

A translational study was designed to analyze the expression of nucleotide excision repair (NER) and homologous recombination (HR) genes as potential predictive biomarkers for trabectedin in soft-tissue sarcoma (STS). This study is part of a randomized phase II trial comparing trabectedin plus doxorubicin versus doxorubicin in advanced STS. Gene expression levels were evaluated by qRT-PCR, while CUL4A protein levels were quantified by immunohistochemistry. Expression levels were correlated with patients&rsquo

yearjournalcountryeditionlanguage
2020-04-30Cancers
10.3390/cancers12051128http://dx.doi.org/10.3390/cancers12051128